BIIB
Biogen Inc.
219.10$
+1.7%
vs. previous close
Closing price · As of: Sep 21, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +26.3% | +21.7% | +0.6% | +36.0% | +14.4% | -40.2% | -13.9% | -62.0% | +11.8% | +85.9% | -23.3% | |
| – | -5.8% | +13.7% | +58.3% | -39.8% | -28.6% | -1.6% | +6.7% | +6.3% | -4.6% | +36.1% | +15.8% | |
| – | +3.9% | -4.1% | -17.3% | +23.0% | +15.7% | +8.8% | +20.3% | +6.5% | +4.0% | +10.2% | -0.1% | |
| – | – | -27.6% | +695.1% | -47.4% | -14.1% | +164.3% | +10.3% | -297.9% | – | – | – | |
| – | – | – | +222.5% | +70.0% | -50.2% | -193.9% | – | – | – | – | – | |
| – | +123.4% | -4.2% | +40.8% | -11.2% | -33.2% | +7.2% | -46.6% | -18.5% | +29.6% | +15.5% | -57.3% | |
| – | +195.1% | -45.4% | +19.2% | -30.9% | – | -229.4% | -7.4% | – | -357.3% | -80.5% | +71.6% | |
| – | -89.2% | -100.0% | – | -88.0% | – | – | -84.8% | – | – | – | – | |
| – | +463.8% | -80.0% | +36.5% | +218.8% | +34.8% | +13.8% | -73.1% | -58.3% | -100.0% | – | – | |
| – | – | -100.0% | +20,674.1% | -99.4% | – | +0.0% | -111.6% | +489.5% | – | -447.0% | -97.4% | |
| – | – | -200.1% | +140.9% | +87.9% | +31.0% | -10.0% | -60.4% | -15.7% | – | -598.9% | -55.8% | |
| – | -82.9% | +887.9% | -173.9% | – | – | -193.7% | – | +24.5% | -304.6% | – | -52.2% | |
| – | +17.0% | +25.6% | -4.6% | +43.9% | +23.8% | -44.0% | -9.1% | -65.8% | +8.0% | +103.6% | -18.5% |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.